GLYC
GlycoMimetics, Inc.
Set alert
52-week range unavailable
- YTD
- -36.93%
- 1 year
- -41.94%
- Open
- 16.25
- Prev close
- 15.71
- Mkt cap
- 13.96M
- Vol
- 612
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 15.52
- High
- 17.39
- Forward P/E
- -2.41
- Beta
- 1.84
- Short ratio
- 1.07
- Inst. own
- 47.91%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Oct 2, 2024
- 50-d avg
- 0.2958
- 200-d avg
- 0.6851
- 1y target
- 1.00
Key statistics
- Market cap
- 13.96M
- Enterprise value
- 3.82M
- Trailing P/E
- 0.00
- Forward P/E
- -2.41
- PEG ratio
- 0.00
- Price / sales
- 1396.08
- Price / book
- 0.36
- EPS (TTM)
- -0.62
- Beta
- 1.84
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 10.00K
- Revenue growth
- 0.00%
- Free cash flow
- -22.15M
- Total cash
- 22.39M
- Total debt
- 448.77K
- Return on equity
- -104.49%
- Shares outstanding
- 64.48M
- Short % of float
- 12.61%
- 50-day average
- 0.2958
- 200-day average
- 0.6851
Analyst view
Consensus: none
- Strong buy0
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Oct 2, 2024
Expected Oct 2, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | 0.00 | -0.15 | — | — |
| Oct 2, 2024 | Jun 1, 2024 | -0.16 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.16 | -0.17 | -0.01 | -6.25% |
| Mar 27, 2024 | Dec 1, 2023 | -0.15 | -0.14 | +0.01 | +6.67% |
| Nov 3, 2023 | Sep 1, 2023 | -0.14 | -0.14 | 0.00 | 0.00% |
| Aug 2, 2023 | Jun 1, 2023 | -0.18 | -0.13 | +0.05 | +27.78% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 26, 2024 | TD Cowen | down | Buy | Hold |
| Jun 4, 2024 | HC Wainwright & Co. | reit | — | Neutral |
| May 6, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Mar 27, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Dec 22, 2023 | Capital One | init | — | Overweight |
| Aug 3, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
About GlycoMimetics, Inc.
GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- glycomimetics.com
News
- Crescent Biopharma Completes Closing of Merger with GlycoMimetics and Previously Announced Private Placement of $200 Million
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals
- Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
- GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC
- Crescent Biopharma Appoints David Lubner to Board of Directors
- 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders
- Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference
Your note
Sign in to keep a note on GLYC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ANDREWS PATRICIA S | Director | Stock Award(Grant) | Dec 28, 2023 | 58,608 |
| GOLDBERG MARK ALAN | Director | Stock Award(Grant) | Mar 27, 2024 | 36,325 |
| HAHN BRIAN M | Chief Financial Officer | Purchase | Jun 17, 2024 | 70,643 |
| INVUS PUBLIC EQUITIES ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Jul 29, 2024 | 0 |
| JOHNSON BRUCE S | Officer | Purchase | May 7, 2023 | 138,980 |
| JUNIUS DANIEL M | Director | Stock Award(Grant) | Mar 27, 2024 | 98,459 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BVF Inc. | 14.80% | 9,544,262 | 2.07M | Sep 29, 2024 |
| Vanguard Group Inc | 4.14% | 2,670,208 | 578.10K | Sep 29, 2024 |
| Siren, L.L.C. | 3.05% | 1,965,114 | 425.45K | Sep 29, 2024 |
| Renaissance Technologies, LLC | 1.21% | 781,100 | 169.11K | Sep 29, 2024 |
| Blackrock Inc. | 1.13% | 727,858 | 157.58K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.81% | 521,223 | 112.84K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.99% | 1,925,297 | 416.83K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.13% | 730,599 | 158.17K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 297,994 | 64.52K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.18% | 112,959 | 24.45K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.13% | 80,838 | 17.50K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.10% | 64,457 | 13.95K | Oct 30, 2024 |